Antibiotics: The Quest For New Super Drugs: Technologies, Markets, Competitors And Opportunities: 2017-2022 Analysis And Forecasts
LONDON, Aug. 10, 2017 /PRNewswire/ -- Abstract
• Antibiotics are drugs used to treat infections that are caused by bacteria.
• The introduction of antibiotics is recognized as one of the most transformative events in medicine.
• Prior to the introduction of the first antibiotics in the 1930s and 1940s, bacterial infections were often fatal, and invasive surgery was accompanied by a high risk of infectious complications.
Download the full report: https://www.reportbuyer.com/product/5001061/
• Today, antibiotics are used routinely to treat and prevent infection.
• However, drug- and multi-drug-resistant bacterial strains pose a serious threat in the clinical setting as they directly contribute to an increase in morbidity and mortality, as compared to the underlying disease itself.
• Due to antibiotic resistance, new antibiotic super drugs are desperately needed to fight infections like MRSA, CRE, ESBLs and C. difficile.
• And that is beyond dealing with diseases like drug-resistant Gonorrhea, which affects an estimated 78 million people globally, or TB, which affects 10 million people worldwide, or even the 1 million+ people in the U.S. who get hospitalized with Pneumonia annually.
• Or bioweapons like Anthrax.
• Unfortunately, it is hard to discover new antibiotics.
• Further compounding the problem, from approximately 20 traditional pharmaceutical companies investing in antibiotic research in the 1980s, there are now only five with significant active internal research programs.
• As a result, most novel antibiotic development is now being conducted by small biotech companies.
• Over the last few years there has been a growing realization among the various stakeholders (Industry players, governments, authorities and medical charities) that something needs to be done to address the issues impacting antibiotic R&D, and avoid the looming socio-economic burden of antimicrobial resistance.
• Current antibiotics work now, for the most part.
• But if an epidemic of one of the multi-drug-resistant strains rapidly spreading across the globe happens, it will be too late to start funding the discovery of new antibiotics.
• The need to invest is now, so there are options when the inevitable next black death appears.
• This report addresses these issues.
• Specifically, it provides:
• Antibiotics Overview.
• Quest for Super Antibiotic Drugs.
• Antibiotics Market.
• Company Profiles.
Download the full report: https://www.reportbuyer.com/product/5001061/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article